生血宁片治疗维持性腹膜透析患者肾性贫血的临床观察  

Clinical observation of Shengxuening tablets in the treatment of renal anemia in maintenance peritoneal dialysis

作　　者：张娟[1] 吴小燕[1] 

机构地区：[1]武汉大学中南医院肾内科,武汉430071

出　　处：《临床肾脏病杂志》2016年第8期492-495,共4页Journal Of Clinical Nephrology

摘　　要：目的观察中成药生血宁片治疗维持性腹膜透析患者肾性贫血的临床疗效及对铁代谢指标、营养不良和微炎症状态的影响。方法选取武汉大学中南医院维持性腹膜透析肾性贫血患者56例,随机分为治疗组和对照组,治疗组口服生血宁片,对照组口服多糖铁复合物胶囊,两组均同时联合皮下注射重组人促红细胞生成素针。治疗12周后观察和比较2组患者治疗前后血红蛋白、红细胞比容、血清铁蛋白、转铁蛋白饱和度、血清肌酐、白蛋白、超敏C反应蛋白等指标变化,同时观察治疗中的不良反应。结果 2组患者在治疗前的贫血指标之间差异无统计学意义(P>0.05),治疗后治疗组及对照组患者贫血治疗的总有效率分别为92.9%及82.1%,治疗组总有效率明显高于对照组(P<0.01);治疗后两组患者的贫血指标较治疗前有显著变化(P<0.05),治疗组用药后血红蛋白、红细胞比容、血清铁蛋白、转铁蛋白饱和度、血清白蛋白均较治疗前明显升高(P<0.05),与对照组相比贫血指标差异有统计学意义(P<0.05);治疗组超敏C反应蛋白水平较治疗前有所下降,但差异无统计学意义(P>0.05)。对照组患者有7例不良反应,而治疗组患者无一例不良反应发生,其不良反应发生明显低于对照组。结论生血宁片可有效纠正腹膜透析患者贫血状态,改善铁代谢和营养不良,同时并未增加腹透患者体内微炎症状态。采用生血宁片联合促红细胞生成素治疗维持性腹膜透析患者肾性贫血的临床疗效明显,且未见明显不良反应。Objective To observe the clinical effectiveness of traditional Chinese medicine Shengxuening tablets in the treatment of renal anemia in maintenance peritoneal dialysis patients, and the influence on iron metabolism indexes, renal malnutrition and micro inflammatory state. Methods Fifty-six cases of maintenance peritoneal dialysis patients with renal anemia were randomly divided into treatment group and control group. The patients in the treatment group were given Shengxuening tablets, and those in the control group were treated with oral administration of polysaccharide iron complex capsules. Both groups were subcutaneously injected with recombinant human erythropoietin. After 12 weeks of treatment, anemia index, clinical effectiveness and adverse reaction were observed and compared between the two groups before and after treatment, such as hemoglobin, red blood cell hematocrit （HCT）, serum ferritin （SF）, transferrin saturation （TSAT）, serum creatinine （SCR）, albumin （ALB）, high sensitive C reaction protein （hs-CRP）, etc. Results There were no significant differences between the two groups in the anemia index before treatment （P〉0. 05）. After 12 weeks of treatment, the total effective rate was 92. 9% in the treatment group, significantly higher than in the control group （82. 1%） （P〈0.01）. Hemoglobin, red blood cell specific volume, SF, TSF, and serum albumin in the treatment group after treatment were significantly increased as comparing with those before treatment （P〈 0. 05）. The level of Hs-CRP in the treatment group decreased as compared with that before treatment, but the difference was not statistically significant （P〉0. 05）.There were 7 cases of adverse reactions in the control group, and no adverse reactions occurred in the treatment group. Conclusions Shengxuening tablets can effectively ameliorate the anemia in peritoneal dialysis patients, improve iron metabolism and malnutrition, also did not increase microinflammatory state in peritoneal dialysis pa

关 键 词：肾性贫血 腹膜透析 微炎症 

分 类 号：R692.5[医药卫生—泌尿科学] R556[医药卫生—外科学]